Vnitřní lékařství 5/2021

PŘEHLEDOVÉ ČLÁNKY Role zánětu a imunity u aterosklerózy a možné způsoby jejich ovlivnění 308 | 8. Koenig W. High-sensitivity C-reactive protein and atherosclerotic disease: from impro- ved risk prediction to risk-guided therapy. Int. J Cardiol 2013; 168: 5126–5134. 9. Quispe R, Michos ED, Martin SS et al. High-sensitivity C-reactive protein discordance with atherogenic lipid measures and incidence of atherosclerotic cardiovascular disea- se in primary prevention: the ARIC study. J Am Heart Assoc 2020; 9: e013600. doi: 10.1161/ JAHA.119.013600. 10. Ross R. Atherosclerosis – aninflammatory disease. N Engl J Med 1999; 340: 115–126. 11. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cho- lesterol and fatty acid synthesis in the liver. J Clin Invest. 2002; 109: 1125–1131. 12. Gurcel L, Abrami L, Girardin S et al. Caspase-1 activation of lipid metabolic path- ways in response to bacterial pore-forming toxins promotes cell survival. Cell 2006; 126: 1134–1145. 13. Antonopoulos AS, Margaritis M, Lee R et al. Statins as anti-inflammatory agents in atherogenesis: molekular rmechanisms and lessons from the recent clinical trials. Curr Pharm Des 2012; 18: 1519–1530. 14. Sahebkar A, Giosia PD, Stamerra CA et al. Effect of monoclonal antibodies to PCSK9 on high sensitivity C-reactive protein levels: a metaanalysis of 16 randomised controlled treatment arms. Br J Clin Pharmacol 2016; 81(6): 1175–1190. 15. Cao YX, Li S, Liu HH, Li JJ. Impact of PCSK9 monoclonal antibodies on circulating hs-CRP levels: a systematic review and meta analysis of randomised controlled trials. 16. Tardif JC, Kouz S, Waters DD et al. Efficacy and safety of low-dose kolchicine after myo- cardial infarction. N Engl J Med 2019; 381: 2497–2505. 17. Nidorf SM, Fiolet ATL, Mosterd A. Colchicine in patients with chronic coronary disea- se. N Engl J Med 2020; 383: 1838–1847. 18. Ridker PM, Everett BM, Pradhan A et al. Low-dose methotrexate for the prevention of atherosclerotic events. N Engl J Med 2019; 380: 752–762. 19. Ridker PM, Everett BM, Thuren T et al. Antiinflamatory therapy with canakinumab for atherosclerotic disease. N Engl J Med 2017; 377: 1119–1131. 20. Abraham M, Wald H, Vanzel-Ohayon D et al. Development of novel promiscuous anti-chemokine peptibodies for treating autoimmunity and inflammation. Front Immu- nol Frontiers 2017; 8: 1432. 21. Hundelshausen von P, Agten SM, Eckardt V et al. Chemokine interactome mapping enables tailored intervention in acute and chronic inflammation. Sci Transl Med 2017; 9: eaah6650. 22. O´Neill LAJ, Kishton RJ, Rathmell J. A guide to immunometabolism for immunologist. Nat Rev Immunol 2016; 16: 553–565. 23. Mancini SJ, Boyd D, Katwan OJ et al. Canagliflozin inhibits interleukin-1beta-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and –independent mechanism. Sci Rep 2018; 8(1): 5276. 24. Chackerian B, Remaley A. Vaccine strategies for lowering LDL by immunization against proprotein invertase subtilisin/kexin type 9. Curr Opin Lipidol 2016; 27: 345–350. 25. Piepoli MF, Hoes AW, Agewall S et al. 2016 European Guidelines on cardiovascular di- sease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Prac- tice. Eur Heart J 2016; 37: 2315–2381. 26. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Pennells L et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 2012; 367: 1310–1320.